VIDEO: The biggest challenges in the treatment of AMD

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.

The biggest challenge in treating neovascular AMD really is around the durability of the drug. Most patients do respond to the therapy, and in fact you can cut the interval down to even every four weeks in some patients who need it that frequently. And even in that four week category, we can maintain or restore significant amount of vision. About 90% of people maintain vision, about 35 to 40% of people have a three line gain in visual acuity. So the only issue with that is the amount of injections needed and the durability drug is not great sometimes. And so therefore in real world situations, patients don't get all the treatments they necessarily need. The average patient needs seven injections or more from what we've learned in clinical studies in order to maintain or improve visual acuity per year. And that is unfortunately difficult to do in real world clinical practice.